Recent BMY News
- Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 06/21/2024 11:30:00 PM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab • Business Wire • 06/21/2024 10:59:00 AM
- Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024 • Business Wire • 06/20/2024 10:59:00 AM
- Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors • Business Wire • 06/18/2024 08:16:00 PM
- Bristol Myers Squibb Announces Dividend • Business Wire • 06/18/2024 10:59:00 AM
- U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors • Business Wire • 06/13/2024 08:46:00 PM
- Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial • Business Wire • 06/04/2024 12:00:00 PM
- Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/04/2024 10:59:00 AM
- Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting • Business Wire • 06/03/2024 02:13:00 PM
- Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer • Business Wire • 06/03/2024 12:00:00 PM
- KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer • Business Wire • 06/01/2024 12:00:00 PM
- U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma • Business Wire • 05/30/2024 03:51:00 PM
- Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 05/29/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms • Business Wire • 05/23/2024 09:05:00 PM
- OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News • IH Market News • 05/23/2024 11:40:51 AM
- Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting • Business Wire • 05/23/2024 10:59:00 AM
- Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries • Business Wire • 05/22/2024 10:59:00 AM
- NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb • PR Newswire (US) • 05/22/2024 07:30:00 AM
- NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb • PR Newswire (US) • 05/22/2024 07:30:00 AM
- Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign • Business Wire • 05/21/2024 12:45:00 PM
- Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase) • Business Wire • 05/21/2024 10:59:00 AM
- New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis • Business Wire • 05/16/2024 02:26:00 PM
- Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma • Business Wire • 05/16/2024 12:57:00 AM
- Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More • IH Market News • 05/13/2024 11:16:03 AM
- Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial • Business Wire • 05/10/2024 08:30:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM